Gene delivery specialist VectorBuilder announced plans to invest $50 million to establish a new advanced biomanufacturing and R&D center in Chicago, marking a major expansion of the company’s regional operations.
The new center will combine research and development with manufacturing capabilities across VectorBuilder’s gene delivery portfolio. Planned as a multi-phase project, the facility is expected to begin initial operations in 2027, with further expansion aligned to customer demand and program scale.
The expansion is designed to support a full range of gene delivery capabilities, including plasmids, recombinant viral and nonviral vectors, and genetically engineered cells, with VectorBuilder looking to improve continuity from research-grade constructs to GMP manufacturing.
“Despite recent volatility in the CGT field, we see strong long-term momentum in genetic medicine,” said Bruce Lahn, Ph.D., chief scientist of VectorBuilder. “This investment reflects our conviction that gene delivery will be a defining factor in the next phase of the industry.”
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!